Jurgen B. Wolf
Experienced in Metastatic Brain Tumor

Jurgen B. Wolf

Kerpener Str. 62, 
Koeln, NW, DE 
Clinical Trials:Currently Recruiting for 1 Trial
Experienced in Metastatic Brain Tumor
Kerpener Str. 62, 
Koeln, NW, DE 
OverviewLocationsClinical Research

Overview

Jurgen Wolf practices in Koeln, Germany. Wolf is rated as an Experienced expert by MediFind in the treatment of Metastatic Brain Tumor. Their top areas of expertise are Non-Small Cell Lung Cancer (NSCLC), Lung Cancer, Small Cell Lung Cancer (SCLC), Milia, and Tissue Biopsy.

Their clinical research consists of co-authoring 256 peer reviewed articles and participating in 10 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, they have co-authored 1 article and participated in 1 clinical trial in the study of Metastatic Brain Tumor.

Locations

Kerpener Str. 62, Koeln, NW, Germany
Other Locations
Kerpener Str. 62, Koeln, NW 50931, Germany
Gleueler Str. 24, Koeln, NW 50931, Germany

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

10 Clinical Trials

A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
A Phase 1/2, Open-Label, Multi-Center, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics, and Anti-Tumor Activity of TPX-0005 in Patients With Advanced Solid Tumors Harboring ALK, ROS1, or NTRK1-3 Rearrangements (TRIDENT-1)
Enrollment Status: Recruiting
Publish Date: July 10, 2025
Intervention Type: Drug
Study Drug: Repotrectinib
Study Phase: Phase 1/Phase 2
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
An Open-Label, Multicenter, Global Phase 2 Basket Study of Entrectinib for the Treatment of Patients With Locally Advanced or Metastatic Solid Tumors That Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements
Enrollment Status: Active_not_recruiting
Publish Date: September 05, 2025
Intervention Type: Drug
Study Drug: Entrectinib
Study Phase: Phase 2
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
A Phase 1/2 Study of Oral Selpercatinib (LOXO-292) in Patients With Advanced Solid Tumors, Including RET Fusion-Positive Solid Tumors, Medullary Thyroid Cancer, and Other Tumors With RET Activation (LIBRETTO-001)
Enrollment Status: Active_not_recruiting
Publish Date: June 04, 2025
Intervention Type: Drug
Study Drug: Selpercatinib
Study Phase: Phase 1/Phase 2
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
A Randomized Phase 3 Multicenter Open-Label Study to Compare the Efficacy of TAK-788 as First-Line Treatment Versus Platinum-Based Chemotherapy in Patients With Non-Small Cell Lung Cancer With EGFR Exon 20 Insertion Mutations
Enrollment Status: Active_not_recruiting
Publish Date: April 22, 2025
Intervention Type: Drug
Study Drugs: TAK-788, Pemetrexed, Cisplatin, Carboplatin
Study Phase: Phase 3
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
LIBRETTO-431: A Multicenter, Randomized, Open-Label, Phase 3 Trial Comparing Selpercatinib to Platinum-Based and Pemetrexed Therapy With or Without Pembrolizumab as Initial Treatment of Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer
Enrollment Status: Active_not_recruiting
Publish Date: April 20, 2025
Intervention Type: Drug
Study Drugs: Selpercatinib, Carboplatin, Cisplatin, Pemetrexed, Pembrolizumab
Study Phase: Phase 3
A Single Arm Phase II Trial Evaluating the Activity of Alectinib for the Treatment of Pretreated RET-rearranged Advanced NSCLC
A Single Arm Phase II Trial Evaluating the Activity of Alectinib for the Treatment of Pretreated RET-rearranged Advanced NSCLC
Enrollment Status: Terminated
Publish Date: April 08, 2025
Intervention Type: Drug
Study Drug: Alectinib
Study Phase: Phase 2
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation
Enrollment Status: Approved_for_marketing
Publish Date: January 17, 2025
Intervention Type: Drug
Anti-PD-L1 Antibody MEDI4736 in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC). A Multicenter Single-arm Phase II Trial.
Anti-PD-L1 Antibody MEDI4736 in Addition to Neoadjuvant Chemotherapy in Patients With Stage IIIA(N2) Non-small Cell Lung Cancer (NSCLC). A Multicenter Single-arm Phase II Trial.
Enrollment Status: Completed
Publish Date: April 15, 2024
Intervention Type: Drug
Study Drug: MEDI4736
Study Phase: Phase 2
A Phase II Trial to Evaluate Efficacy and Safety of Erdafitinib in Patients With Advanced Non Small Cell Lung Carcinoma (NSCLC) Harboring Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations After Relapse of Standard Therapy.
A Phase II Trial to Evaluate Efficacy and Safety of Erdafitinib in Patients With Advanced Non Small Cell Lung Carcinoma (NSCLC) Harboring Fibroblast Growth Factor Receptor (FGFR) Genetic Alterations After Relapse of Standard Therapy.
Enrollment Status: Terminated
Publish Date: June 09, 2023
Intervention Type: Drug
Study Drug: Erdafitinib
Study Phase: Phase 2
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
Enrollment Status: Completed
Publish Date: July 30, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

256 Total Publications

Germany's national genomDE strategy.
Germany's national genomDE strategy.
Journal: Nature medicine
Published: October 15, 2025

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Wolf's expertise for a condition
ConditionClose
    View All 24 Experienced Conditions
    Want to save this expert for later?
    Sign Up
    Not sure about your diagnosis?
    Check Your Symptoms
     
     
     
     
    Learn about our expert tiers
    Learn More
    Are you the provider on this profile?
    Claim Profile